Pure Bioscience Valuation
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Pure Bioscience seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Pure Bioscience from analyzing the company fundamentals such as Operating Margin of (1.98) %, return on equity of -1.29, and Shares Outstanding of 111.36 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Pure Bioscience's price fluctuation is very steady at this time. Calculation of the real value of Pure Bioscience is based on 3 months time horizon. Increasing Pure Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pure pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Pure Bioscience. Since Pure Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pure Pink Sheet. However, Pure Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0878 | Real 0.0824 | Hype 0.09 | Naive 0.1 |
The real value of Pure Pink Sheet, also known as its intrinsic value, is the underlying worth of Pure Bioscience Company, which is reflected in its stock price. It is based on Pure Bioscience's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pure Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pure Bioscience helps investors to forecast how Pure pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pure Bioscience more accurately as focusing exclusively on Pure Bioscience's fundamentals will not take into account other important factors: Pure Bioscience Total Value Analysis
Pure Bioscience is at this time projected to have valuation of 13.51 M with market capitalization of 13.36 M, debt of 239 K, and cash on hands of 511 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pure Bioscience fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.51 M | 13.36 M | 239 K | 511 K |
Pure Bioscience Investor Information
About 41.0% of the company outstanding shares are owned by corporate insiders. The book value of Pure Bioscience was at this time reported as 0.03. The company recorded a loss per share of 0.04. Pure Bioscience had not issued any dividends in recent years. The entity had 1:8 split on the 15th of August 2012. Based on the measurements of operating efficiency obtained from Pure Bioscience's historical financial statements, Pure Bioscience is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Pure Bioscience Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pure Bioscience has an asset utilization ratio of 41.32 percent. This indicates that the Company is making $0.41 for each dollar of assets. An increasing asset utilization means that Pure Bioscience is more efficient with each dollar of assets it utilizes for everyday operations.Pure Bioscience Ownership Allocation
Pure Bioscience owns a total of 111.36 Million outstanding shares. Pure Bioscience has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pure Bioscience Profitability Analysis
The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pure Bioscience's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pure Bioscience and how it compares across the competition.
About Pure Bioscience Valuation
The pink sheet valuation mechanism determines Pure Bioscience's current worth on a weekly basis. Our valuation model uses a comparative analysis of Pure Bioscience. We calculate exposure to Pure Bioscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pure Bioscience's related companies.PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.
8 Steps to conduct Pure Bioscience's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Pure Bioscience's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Pure Bioscience's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Pure Bioscience's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Pure Bioscience's revenue streams: Identify Pure Bioscience's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Pure Bioscience's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Pure Bioscience's growth potential: Evaluate Pure Bioscience's management, business model, and growth potential.
- Determine Pure Bioscience's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Pure Bioscience's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Pure Bioscience Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pure Bioscience does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 88 M | |
| Retained Earnings | -129.3 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |